Loading organizations...
Key people at Phyto Partners.
Phyto Partners is a venture capital firm providing debt and equity capital to privately held cannabis companies. It strategically invests across the cannabis value chain, emphasizing ancillary businesses crucial for industry growth. The diverse portfolio spans agriculture technology, branded products, biotechnology, education, and specialized software solutions.
Founded in June 2015 by Larry Schnurmacher, Phyto Partners emerged from the recognized investment opportunities within the nascent regulated cannabis sector. Schnurmacher, as Managing Partner, established the firm to offer capital and critical strategic support to businesses navigating the industry’s complex regulatory environment.
The firm primarily serves privately held cannabis businesses and their essential service providers, addressing capital and operational needs. Phyto Partners’ vision focuses on empowering its portfolio to manage compliance, build brands, connect with customers, and enhance efficiency, fostering the long-term professionalization of the legal cannabis industry.
Key people at Phyto Partners.
Phyto Partners has 11 tracked investments across 9 companies. The latest tracked deal is $4.6M Seed in Wonder Sciences in June 2022.
# High-Level Overview
Phyto Partners is a venture capital firm that provides debt and equity capital to privately held cannabis companies.[1] Founded in 2015, the firm has deployed capital into 30 distinct portfolio companies across the cannabis supply chain, with a strategic focus on ancillary businesses that support licensed operators.[1][2]
The firm's investment philosophy centers on identifying companies that help licensed cannabis producers comply with regulations, manage operations, connect with customers, build brands, reduce costs, and operate more efficiently.[1] Rather than being a passive investor, Phyto Partners positions itself as "more than a check" by offering financial sponsorship, strategic support, and business development assistance while actively facilitating introductions to potential customers, investors, and M&A targets.[1] The firm has invested approximately $20 million across its portfolio, with notable investments in companies like Flowhub (compliance technology), LeafLink (distribution logistics), and Baker (branded products).[2][5]
# Origin Story
Phyto Partners was founded in 2015 by Larry Schnurmacher, who previously worked as a financial advisor at Morgan Stanley.[5] Schnurmacher's transition from Wall Street to cannabis venture capital was driven by his research into the growing legal cannabis industry, which he recognized as an emerging investment opportunity before mainstream financial institutions took notice.[5] The firm's founding team includes Schnurmacher and his founding partner, supported by a group of analysts and a strong advisory board with experience in healthcare, venture capital, and private equity.[5]
The firm's early success in the cannabis space—helping grow the industry from $4 billion in sales in 2015 to nearly $25 billion in 2021—has positioned it to expand beyond cannabis.[4] This success led to the launch of Phyto Psyche, a psychedelic-focused fund that applies the same investment approach to the emerging neurowellness and brain health sector.[4]
# Core Differentiators
# Role in the Broader Tech Landscape
Phyto Partners arrived at a pivotal moment in cannabis legalization, when the industry was transitioning from prohibition to regulated markets. The firm recognized that compliance, operational efficiency, and brand-building technologies would be critical infrastructure for a maturing industry—a thesis that proved correct as companies like Flowhub scaled from fewer than 100 clients to nearly 500.[5]
The firm's success in cannabis has broader implications for emerging regulated industries. By demonstrating that ancillary service providers often capture more sustainable value than direct operators in highly regulated markets, Phyto Partners has established a replicable playbook. This insight directly informed the launch of Phyto Psyche, which applies the same thesis to psychedelics and neurowellness—sectors expected to follow a similar regulatory trajectory as cannabis did over the past decade.
# Quick Take & Future Outlook
Phyto Partners exemplifies how venture capital can thrive in regulated industries by focusing on the infrastructure and services layer rather than the commodity production layer. As cannabis matures and consolidates, the firm's portfolio companies—particularly data and compliance platforms—are positioned to become essential utilities for licensed operators.
The expansion into psychedelics signals confidence that the firm's core competency lies not in cannabis specifically, but in identifying and funding critical service providers in emerging regulated markets. As neurowellness and psychedelic-assisted therapies move toward legalization and clinical adoption, Phyto Partners' early positioning and industry relationships could prove similarly prescient. The firm's ability to build synergistic portfolio ecosystems and facilitate strategic partnerships will likely remain a key competitive advantage as these markets develop.
